methyl 3-cyclohexyl-2-(4-methoxyphenyl)-1H-indole-6-carboxylate | 848485-50-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 3-cyclohexyl-2-(4-methoxyphenyl)-1H-indole-6-carboxylate
• CAS: 848485-50-7
• 化学式: C₂₃H₂₅NO₃
• 分子量: 363.456
• InChiKey: WHRWLZRFYOAXIE-UHFFFAOYSA-N

物化性质

• 沸点：
  549.6±50.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-cyclohexyl-2-(4-methoxyphenyl)-1H-indole-6-carboxylate 在 sodium hydride 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 Methyl 3-cyclohexyl-2-(4-methoxyphenyl)-1-[2-[4-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butylamino]-2-oxoethyl]indole-6-carboxylate
  参考文献：
  名称：

  Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series

  摘要：

  Novel conformationaly constrained 1,6- and 2,6-macrocyclic HCV NS5b polymerase inhibitors, in which either the nitrogen or the phenyl ring in the C2 position of the central indole core is tethered to an acylsulfamide acid bioisostere, have been designed and tested for their anti-HCV potency. This transformational route toward non-zwitterionic finger loop-directed inhibitors led to the discovery of derivatives with improved cell potency and pharmacokinetic profile. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.097
• 作为产物：
  描述：

  3-氨基-4-羟基苯甲酸甲酯 在 palladium on activated charcoal 吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 1,1,2,3-四甲基胍 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 methyl 3-cyclohexyl-2-(4-methoxyphenyl)-1H-indole-6-carboxylate
  参考文献：
  名称：

  Development and Preliminary Optimization of Indole-N-Acetamide Inhibitors of Hepatitis C Virus NS5B Polymerase

  摘要：

  Allosteric inhibition of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase enzyme has recently emerged as a viable strategy toward blocking replication of viral RNA in cell-based systems. We report here a novel class of allosteric inhibitor of NS5B that shows potent affinity for the NS5B enzyme and effective inhibition of subgenomic HCV RNA replication in HUH-7 cells. Inhibitors from this class have promising characteristics for further development as anti-HCV agents.

  DOI：

  10.1021/jm049122i

文献信息

• [EN] INDOLES AND AZAINDOLES AS ANTIVIRAL AGENTS<br/>[FR] INDOLES ET AZAINDOLES UTILISES COMME AGENTS ANTIVIRAUX
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2005034941A1

  公开（公告）日：2005-04-21

  The present invention relates to indoles and azaindoles of formula (I): wherein X1, X2, X3, X4, A1, Ar1, Ar, n, p and q are as defined herein and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C virus infections.

  本发明涉及式(I)的吲哚和氮杂吲哚，其中X1、X2、X3、X4、A1、Ar1、Ar、n、p和q如本文所定义，并其药用盐，用于预防和治疗丙型肝炎病毒感染。
• Indoles and azaindoles as antiviral agents
  申请人：Avolio Salvatore

  公开号：US20070072911A1

  公开（公告）日：2007-03-29

  The present invention relates to indoles and azaindoles of formula (1): wherein X 1 , X 2 , X 3 , X 4 , A 1 , Ar 1 , Ar, n, p and q are as defined herein and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C virus infections.

  本发明涉及式（1）的吲哚和氮杂吲哚：其中X1，X2，X3，X4，A1，Ar1，Ar，n，p和q如本文所定义，并且其药学上可接受的盐，用于预防和治疗丙型肝炎病毒感染。
• MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS
  申请人：RABOISSON Pierre Jean-Marie Bernard

  公开号：US20100273792A1

  公开（公告）日：2010-10-28

  The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein R 1 ; R 3 ; and R 4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  本发明涉及公式（I）的HCV复制抑制剂，N-氧化物形式，药学上可接受的加盐物，季铵盐和其立体化学异构体形式，其中R1;R3;和R4具有在权利要求中定义的含义。本发明还涉及制备所述化合物的过程，包含它们的制药组合物以及它们在HCV治疗中的使用。
• Macrocyclic Indoles as Hepatitis C Virus Inhibitors
  申请人：Janssen R&D Ireland

  公开号：US20130267511A1

  公开（公告）日：2013-10-10

  The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein R 1 ; R 3 ; and R 4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  本发明涉及公式（I）的HCV复制抑制剂，N-氧化物形式，药学上可接受的加盐物，季铵盐和其立体化学异构体形式，其中R1；R3；和R4具有权利要求中所定义的含义。本发明还涉及制备所述化合物的过程，含有它们的制药组合物以及它们在HCV治疗中的使用。
• [EN] MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] INDOLES MACROCYCLIQUES COMME INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：TIBOTEC PHARM LTD

  公开号：WO2009080836A3

  公开（公告）日：2009-09-17